Skip to content

Longevity

Epitalon

Longevity claims built on an old, narrow and largely unreplicated body of research.

L1MechanisticExperimental / researchPreclinicalVery low confidenceLast reviewed 2026-08-23
SC injection· unapprovedNasal· unapproved

Also known as: epithalon, AEDG peptide

Evidence passport

Last reviewed 2026-08-23

Evidence level
L1Mechanistic
Confidence
Very low confidence
Human efficacy
10/100
Human safety
10/100
Regulatory status
Experimental / research
Development
Preclinical
Routes
SC injection· unapprovedNasal· unapproved
Evidence base
Mostly preclinical
Furthest stage
Not established
Source curation
Sources fully curated
Clinical maturity
Preclinical and historical small-scale human reports

Most of this evidence comes from animals and cells

The supporting research for Epitalon is predominantly preclinical (Level 1–2). That is a legitimate starting point for science and a poor basis for personal decisions. Human results are not simply a scaled-up version of mouse results.

Overview

Human evidence10/100
Preclinical evidence45/100
Human safety evidence10/100

Clinical maturity: Preclinical and historical small-scale human reports

Routes & formulations

Marketed / research routes — never approved

SC injection· unapprovedNasal· unapproved

No approved formulation exists. Research-market material is typically injectable or nasal; no route has controlled human evidence behind it.

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

Peptide lifecycle

  1. Discovery

  2. Preclinical

  3. Phase I

  4. Phase II

  5. Phase III

  6. Approved

PreclinicalFurthest stage not established in our curated record

Historical small-scale human reports exist, but no modern clinical development programme is established.

What it is

A synthetic four-amino-acid peptide derived from a pineal gland extract, promoted for telomere maintenance and lifespan extension.

What people claim

  • Lengthens telomeres
  • Extends human lifespan
  • Restores pineal and circadian function

What the evidence actually says

Most of the supporting literature comes from a narrow historical research tradition, with limited independent replication and methods that would not meet modern standards. Telomerase activation in cell culture is a long way from a longer human life. Human lifespan extension is unproven.

Human evidence

  • Historical small-scale human reports with significant methodological limitations and little independent replication.
  • No modern randomised controlled trials.

Preclinical evidence

  • Cell studies reporting telomerase activation in fibroblast cultures.
  • Rodent studies from a limited research network reporting lifespan or tumour-incidence effects.

Animal and cell findings are Level 1–2 evidence.

Mechanism and pathways

  • Proposed activation of telomerase and telomere maintenance.
  • Proposed modulation of pineal melatonin signalling and circadian rhythm.

Safety and unknowns

  • No meaningful modern human safety data.
  • Chronic telomerase activation has theoretical implications that have not been studied in humans.

Cancer relevance

Theoretical / mechanistic concern only

Telomerase reactivation is a hallmark of many cancers, so deliberately activating it is a legitimate theoretical concern. There is no human evidence that Epitalon causes cancer — and no human evidence that it does not. Unknown is the accurate word.

Regulatory status

Not an approved medicine in major regions. Sold as a research compound. The FDA's 503A Category 2 list flags epitalon as a bulk substance raising significant safety risks for compounding.

Evidence grade

L1MechanisticVery low confidence

Cell, receptor or computational work explaining how something could work.

What would change our rating?

  • Independent replication of telomere effects with modern measurement methods.
  • Any registered randomised controlled trial with objective endpoints.

References and sources

Sources fully curated

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

Evidence change history

  1. 2026-06-15

    Baseline entry: lifespan-extension claims recorded as unsupported.

    L1MechanisticBaseline entry
    Supporting literature is historical, narrow and largely unreplicated. Mechanistic telomerase findings do not establish human outcomes.

Related claims we’ve checked

Unsupported as statedL1MechanisticLongevity

“Epitalon extends human lifespan.”

Unsupported — human lifespan extension has never been demonstrated for any peptide.

  • The supporting literature is old, narrow and largely unreplicated independently.
  • Telomerase activation in cell culture is mechanistic evidence, not a lifespan outcome.
  • Human lifespan trials are extraordinarily hard to run, which is precisely why nobody should claim to have won one.
Last reviewed 2026-06-15Compound profile